Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
stocks
ASX share’s growth story intact despite supply constraints
stocks
ASX healthcare giant rallies despite a fall in profits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,265.80 | 17.60 | -0.19% |
| CAC 40 | 8,453.09 | 48.82 | -0.57% |
| DAX 40 | 25,983.04 | 108.29 | -0.42% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,748.16 | 4.81 | 0.04% |
| HKSE | 25,826.08 | 127.59 | 0.50% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,008.45 | 208.34 | -0.31% |
| NZX 50 Index | 13,918.21 | 1.61 | -0.01% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,054.30 | 11.50 | -0.13% |
| SSE Composite Index | 3,904.73 | 1.01 | 0.03% |